Skip to main content
. 2017 Jan;9(1):123–128. doi: 10.21037/jtd.2017.01.25

Figure 2.

Figure 2

The progression free survival of patients who had received palliative chemotherapy. The median PFS was 19.4 months in patients received cisplatin and docetaxel, and 10.7 months in patients received cisplatin and non-docetaxel regimen (P=0.29). PFS, progression free survival.